Table 1
From: Assessing the risk of birth defects associated with atazanavir exposure in pregnancy
Exposure to any ARV (Jan 1989-Jan 2010) | Exposure to ATV (Jun 2003–Jan 2010) | |
|---|---|---|
Earliest exposure to ARVs | ||
First Trimester | ||
•# of defects/live births | 127/4563 | 8/368 |
•Prevalence (95% CI) | 2.8% (2.3%-3.3%) | 2.2% (0.9%-4.2%) |
Second/Third Trimester | ||
•# of defects/live births | 158/6184 | 5/199 |
•Prevalence (95% CI) | 2.6% (2.2%-3.0%) | 2.5% (0.8%-5.8%) |
Any Trimester | ||
•# of defects/live births | 285/10747 | 13/567 |
•Prevalence (95% CI) | 2.7% (2.3%-3.0%) | 2.3% (1.2%-3.9%) |